» Articles » PMID: 1483495

Effect of Propranolol on Urinary Prostaglandin E2 Excretion and Renal Interlobar Arterial Blood Flow After Furosemide Administration in Patients with Hepatic Cirrhosis

Overview
Specialty Pharmacology
Date 1992 Jan 1
PMID 1483495
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of propranolol on furosemide-stimulated urinary prostaglandin E2 (PGE2) excretion and renal blood flow was evaluated in 12 patients with alcoholic liver cirrhosis. Plasma and urine were collected before and 60 min after furosemide 20 mgI with or without propranolol pretreatment, and plasma renin activity (PRA), plasma aldosterone concentration (PAC), urinary excretion of PGE2 and sodium were determined. The renal interlobar arterial Pulsatility Index (PI), as an index of resistance to blood flow, was also determined before and 60 min after furosemide administration with and without propranolol pretreatment, by using a duplex Doppler ultrasound (Hitachi EUB 565). Urine volume and sodium excretion after furosemide administration were not influenced by the propranolol pretreatment. Furosemide administration significantly increased urinary PGE2 excretion, PRA and PAC, and these effects were significantly reduced by propranolol. Furosemide administration with or without propranolol significantly reduced renal interlobar arterial PI, the average reduction in PI being significantly lower after furosemide administration with propranolol pretreatment. The results demonstrate that propranolol pretreatment significantly influenced the furosemide-induced increase in urinary PGE2 excretion and renal interlobar arterial blood flow in cirrhotic patients.

Citing Articles

Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

Wang J, Lu W, Li J, Zhang R, Zhou Y, Yin Q Exp Ther Med. 2017; 13(5):1977-1985.

PMID: 28565796 PMC: 5443179. DOI: 10.3892/etm.2017.4210.


Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Pea F, Furlanut M Clin Pharmacokinet. 2001; 40(11):833-68.

PMID: 11735605 DOI: 10.2165/00003088-200140110-00004.


Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients.

Stanley A, Bouchier I, Hayes P Gut. 1998; 42(2):283-7.

PMID: 9536956 PMC: 1726998. DOI: 10.1136/gut.42.2.283.

References
1.
Tan S, Mulrow P . Inhibition of the renin-aldosterone response to furosemide by indomethacin. J Clin Endocrinol Metab. 1977; 45(1):174-6. DOI: 10.1210/jcem-45-1-174. View

2.
Fujimura A, Kajiyama H, Ebihara A . The effect of propranolol on urinary prostaglandin E2 after frusemide administration in healthy subjects. Eur J Clin Pharmacol. 1987; 31(5):605-7. DOI: 10.1007/BF00606639. View

3.
Jaffe B, Behrman H, Parker C . Radioimmunoassay measurement of prostaglandins E, A, and F in human plasma. J Clin Invest. 1973; 52(2):398-405. PMC: 302269. DOI: 10.1172/JCI107196. View

4.
Buhler F, LARAGH J, Baer L, Vaughan Jr E, Brunner H . Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972; 287(24):1209-14. DOI: 10.1056/NEJM197212142872401. View

5.
Lebrec D, Poynard T, Bernuau J, Bercoff E, Nouel O, Capron J . A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology. 1984; 4(3):355-8. DOI: 10.1002/hep.1840040301. View